← Back
NeuroTrials.ai
Neurology Clinical Trial Database

PACE

Effect of Capsaicin (8%) Topical System on Sensory Function in Patients With Diabetic Peripheral Neuropathy: Analysis of the PACE Study

Year of Publication: 2026

Authors: Katz NP, Allen S, Carnevale A, ..., Simpson DM

Journal: Muscle & Nerve

Citation: Muscle & Nerve, 2026; 73:1109–1117

Link: https://doi.org/10.1002/mus.70237


Clinical Question

Do repeated 30-minute high-concentration capsaicin (8%) topical system treatments improve peripheral sensory function in patients with painful diabetic peripheral neuropathy with baseline sensory deficits?

Bottom Line

In this post hoc analysis of PACE, repeated 30-minute HCCTS treatments plus standard of care improved peripheral sensory function over 12 months in patients with painful diabetic peripheral neuropathy and baseline sensory deficits, with significant improvements in BSPE heat, sharp, and vibration as well as Norfolk QOL-DN total and large-fiber subscale scores. If confirmed in dedicated trials, sensory improvements may reduce diabetic foot complications by restoring protective sensation.

Major Points

  • Analysis 1 (n=156): Repeated 30-min HCCTS treatments led to shifts from below-normal to normal sensory function at Month 12 in 21.1% (heat), 26.4% (cold), 22.8% (sharp), 4.2% (vibration), and 9.8% (deep tendon reflex) of tests
  • Positive shifts in BSPE scores from baseline were more common than negative shifts across all five sensory modalities (heat, cold, sharp, vibration, deep tendon reflex)
  • Analysis 2 (n=177 with below-normal baseline sensory function): Significant improvements with HCCTS+SOC vs SOC alone in BSPE heat (p=0.009), sharp (p=0.048), and vibration (p=0.008)
  • Norfolk QOL-DN total score significantly improved with HCCTS+SOC vs SOC alone (p<0.001)
  • Norfolk QOL-DN large-fiber subscale significantly improved (p<0.001); no significant difference in small-fiber subscale
  • No significant between-group differences in BSPE cold or deep tendon reflexes
  • Suggests possible neuroregenerative effect of HCCTS, with potential to restore protective sensation and reduce diabetic foot complications if confirmed in dedicated trials

Design

Study Type: Post hoc analysis of Phase III, multinational, open-label, randomized, controlled 52-week safety study

Randomization: 1

Blinding: Open-label for treatment; BSPE assessments blinded to treatment allocation

Allocation: Randomized to 30-min HCCTS+SOC, 60-min HCCTS+SOC, or SOC alone

Enrollment Period: November 2011 to February 2014

Follow-up Duration: 52 weeks (12 months)

Centers: 71

Countries: 11 European countries

Sample Size: 468

Analyzed: 156

Analysis: Analysis 1: descriptive shifts in BSPE sensory tests with LOCF imputation. Analysis 2: two-factor ANOVA with repeated measures (SPSS) comparing 30-min HCCTS+SOC vs SOC alone among patients with below-normal baseline sensory function; no imputation for missing data.

Registration: ClinicalTrials.gov NCT01478607


Inclusion Criteria

  • Age ≥18 years
  • Diagnosis of painful diabetic peripheral neuropathy (PDPN)
  • Type 1 or Type 2 diabetes for at least 1 year before screening
  • For Analysis 2: below-normal sensory function across all modalities at baseline

Exclusion Criteria

  • For Analysis 2: normal function in response to any stimulus at baseline
  • For Analysis 2: missing BSPE or Norfolk QOL-DN data at baseline

Baseline Characteristics

Characteristic30-min HCCTS treatment + SOC (n=156)SOC alone (n=155)
Male74 (47.4%)71 (45.8%)
Female82 (52.6%)84 (54.2%)
Mean Age (SD)60.9 (10.9) years59.1 (10.3) years
Mean Duration of PDPN (SD)4.1 (3.7) years4.4 (3.6) years

Arms

Field30-min HCCTS + SOC60-min HCCTS + SOCControl
N156157155
Intervention30-minute application of high-concentration capsaicin (8%) topical system (QUTENZA) to the feet plus standard of care; retreatment permitted ≥8 weeks apart, up to 7 treatments60-minute application of HCCTS to the feet plus standard of care; retreatment permitted ≥8 weeks apart, up to 7 treatmentsStandard of care alone (determined by treating clinician; could include oral/transdermal opioids up to 80 mg morphine equivalents/day)
Duration12 months12 months12 months

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Changes in sensory function over 12 months as assessed by Brief Sensory Pain Examination (BSPE) and Norfolk QOL-DN with repeated 30-min HCCTS treatments + SOC vs SOC alone among patients with below-normal baseline sensory function (Analysis 2)PrimarySOC alone (n=89)30-min HCCTS + SOC (n=88)Significant improvements with HCCTS+SOC vs SOC alone in BSPE heat, sharp, vibration, and Norfolk QOL-DN total and large-fiber subscaleBSPE heat p=0.009; sharp p=0.048; vibration p=0.008; Norfolk QOL-DN total p<0.001; large-fiber subscale p<0.001
Analysis 1: Shifts from below-normal to normal sensory function at Month 12 (LOCF) in patients receiving 30-min HCCTS + SOCSecondaryHeat: 21.1% of tests shifted from below-normal to normal · Cold: 26.4% of tests shifted from below-normal to normal · Sharp: 22.8% of tests shifted from below-normal to normal · Vibration: 4.2% of tests shifted from below-normal to normal · Deep Tendon Reflex: 9.8% of tests shifted from below-normal to normal
BSPE positive vs negative shifts from baseline across all 5 modalitiesSecondaryFinding: Positive shifts more common than negative shifts for heat, cold, sharp, vibration, and deep tendon reflex
Between-group comparisons without significant differenceSecondaryFinding: No significant difference between HCCTS+SOC and SOC alone in BSPE cold, deep tendon reflexes, or Norfolk QOL-DN small-fiber subscale
Absent sensation at baseline – proportion with positive shiftSecondaryFinding: Percentage with positive shift increased with repeated HCCTS treatments for heat, cold, sharp, and vibration; no apparent increase for deep tendon reflex
Primary PACE analysis (previously reported): HCCTS+SOC was not associated with deterioration in nerve function vs SOC alone over 52 weeks (Norfolk QOL-DN total score decreased 27.6% with 30-min HCCTS+SOC vs 6.7% with SOC alone, indicating improvement)Safety

Subgroup Analysis

Analysis 2 restricted to patients with below-normal sensory function across all modalities at baseline (n=177; HCCTS+SOC n=88, SOC alone n=89)


Criticisms

  • Post hoc analysis — hypothesis-generating, not confirmatory
  • Open-label study design (though BSPE assessments were blinded)
  • Analysis 1 used LOCF imputation, which may bias results
  • Sensory function changes assessed by bedside BSPE rather than quantitative sensory testing (QST) or intraepidermal nerve fiber density (IENFD) measures
  • No statistical testing in Analysis 1 (descriptive only)
  • Improvements seen in both treatment groups, suggesting some natural variability or SOC effect
  • Mechanistic explanation (neuroregeneration) inferred from external literature, not directly demonstrated in this analysis

Funding

Averitas Pharma, Inc. (multiple authors are employees of Averitas Pharma)

Based on: PACE (Muscle & Nerve, 2026)

Authors: Katz NP, Allen S, Carnevale A, ..., Simpson DM

Citation: Muscle & Nerve, 2026; 73:1109–1117

Content summarized and formatted by NeuroTrials.ai.